Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia
2013 (English)In: Psychiatry Research, ISSN 0165-1781, E-ISSN 1872-7123, Vol. 210, no 3, 819-824 p.Article in journal (Refereed) Published
Objectives: Oxidative stress has been implicated in the pathophysiology of schizophrenia. Taurine and glutathione (GSH) have antioxidant and central nervous system protective properties and are proposed to be involved in the pathology of schizophrenia. The aim of this study was to compare the blood and cerebrospinal fluid (CSF) levels of taurine and GSH in patients with schizophrenia medicated with oral olanzapine compared with controls.
Methods: In total, 37 patients with schizophrenia being medicated with olanzapine and 45 healthy volunteers were recruited. Taurine and GSH levels were analysed in plasma and CSF and correlated to symptoms and level of function.
Results: Plasma taurine levels were elevated in patients compared with controls (p=0.000003). No differences were found between patients and controls regarding taurine in CSF or GSH concentrations in plasma and CSF.
Conclusion: The significantly higher levels of plasma but not CSF taurine in patients with schizophrenia treated with olanzapine compared with controls may implicate the involvement of taurine in the pathophysiology of the disease. The absence of GSH differences in plasma and CSF between patients and controls is interesting in the perspective of earlier research proposing a dysregulation of GSH metabolism as a vulnerability factor for the development of schizophrenia.
Place, publisher, year, edition, pages
Elsevier , 2013. Vol. 210, no 3, 819-824 p.
Glutathione; taurine; schizophrenia; cerebrospinal fluid; olanzapine
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-84601DOI: 10.1016/j.psychres.2013.09.014ISI: 000329417500024OAI: oai:DiVA.org:liu-84601DiVA: diva2:560530